arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Niagen Bioscience, Inc.

NAGE
$2.10 ▼ -0.42 (-16.67%) at close
Materials ·Medicinal Chemicals & Botanical Products ·USMedicinal Chemicals & Botanical Products
17 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
80
Health
Good
Bullish
auto_awesome

Analytical Summary

Niagen Bioscience, Inc. shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $166.3M
Dividend Yield —
Revenue Growth 29.9% ↗
Op. Margin 12.6% ↗
ROIC 20.3% ↗
FCF / Share $0.17 ↗
Trailing P/E 9.6x
Price / Book 2.2x
FCF Yield 8.1%
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

17-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$129.42M
↑ +29.9% —
Net Income Profit after all expenses
$17.38M
↑ +103.3% —
Operating Margin Operating profit as % of sales
12.6%
↑ +62.1% 62th
FCF / Share Free cash flow per share
$0.17
↑ +6.9% —
Long-Term Debt Long-term obligations
$0.00
↓ -100.0% —
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
65
Returns
89
Financial Health
100
Cash Quality ↓
52

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 17 years · 67 quarters